Suppr超能文献

脑脊液生物标志物在认知障碍评估中的临床应用:一项系统评价和荟萃分析。

Clinical utility of cerebrospinal fluid biomarkers in the evaluation of cognitive impairment: a systematic review and meta-analysis.

作者信息

Hazan Jemma, Wing Michelle, Liu Kathy Y, Reeves Suzanne, Howard Robert

机构信息

Division of Psychiatry, University College London, London, UK

Division of Psychiatry, University College London, London, UK.

出版信息

J Neurol Neurosurg Psychiatry. 2023 Feb;94(2):113-120. doi: 10.1136/jnnp-2022-329530. Epub 2022 Sep 12.

Abstract

BACKGROUND

The analytical and clinical validity of cerebrospinal (CSF) biomarkers has been extensively researched in dementia. Further work is needed to assess the ability of these biomarkers to improve diagnosis, management and health outcomes in the clinical setting OBJECTIVES: To assess the added value and clinical utility of CSF biomarkers in the diagnostic assessment of cognitively impaired patients under evaluation for Alzheimer's disease (AD).

METHODS

Systematic literature searches of Medline, EMBASE, PsycINFO and Web of Science research databases were conducted on 17 December 2022. Data from relevant studies were extracted and independently screened for quality using a tool for bias. Clinical utility was measured by clinicians' changes in diagnosis, diagnostic confidence and patient management (when available), after their examination of patients' CSF biomarkers. Cost-effectiveness was assessed by consideration of additional cost per patient and quality-adjusted life years.

RESULTS

Searches identified 17 studies comprising 2090 patient participants and 593 clinicians. The meta-analysis revealed that clinicians' use of CSF biomarkers resulted in a pooled percentage change in diagnosis of 25% (95% CI 14 to 37), an increase in diagnostic confidence of 14% (95% CI 9 to 18) and a pooled proportion of patients whose management changed of 31% (95% CI 12 to 50). CSF biomarkers were deemed cost-effective, particularly in memory services, where pre-test AD prevalence is higher compared with a primary care setting.

CONCLUSIONS

CSF biomarkers can be a helpful additional diagnostic tool for clinicians assessing patients with cognitive impairment. In particular, CSF biomarkers consistently improved clinicians' confidence in diagnosing AD and influenced on diagnostic change and patient management. Further research is needed to study the clinical utility of blood-based biomarkers in the clinical setting.

摘要

背景

脑脊液(CSF)生物标志物的分析和临床有效性已在痴呆症研究中得到广泛研究。需要进一步开展工作,以评估这些生物标志物在临床环境中改善诊断、管理和健康结局的能力。目的:评估脑脊液生物标志物在对疑似阿尔茨海默病(AD)进行评估的认知障碍患者的诊断评估中的附加价值和临床效用。

方法

于2022年12月17日对Medline、EMBASE、PsycINFO和Web of Science研究数据库进行了系统的文献检索。提取相关研究的数据,并使用偏倚工具独立筛选质量。临床效用通过临床医生在检查患者脑脊液生物标志物后诊断、诊断信心和患者管理(如适用)的变化来衡量。通过考虑每位患者的额外成本和质量调整生命年评估成本效益。

结果

检索确定了17项研究,包括2090名患者参与者和593名临床医生。荟萃分析显示,临床医生使用脑脊液生物标志物导致诊断的合并百分比变化为25%(95%CI 14至37),诊断信心增加14%(95%CI 9至18),管理发生变化的患者合并比例为31%(95%CI 12至50)。脑脊液生物标志物被认为具有成本效益,特别是在记忆服务中,与初级保健环境相比,其检测前AD患病率更高。

结论

脑脊液生物标志物可以成为临床医生评估认知障碍患者的有用辅助诊断工具。特别是,脑脊液生物标志物持续提高了临床医生诊断AD的信心,并影响诊断变化和患者管理。需要进一步研究以探讨基于血液的生物标志物在临床环境中的临床效用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验